105 related articles for article (PubMed ID: 11768029)
1. Serum and tissue c-erb B2, bcl-2, and mutant p53 oncoprotein levels in nasopharyngeal cancer.
Yazici H; Altun M; Hafiz G; Dalay N
Cancer Invest; 2001; 19(8):773-8. PubMed ID: 11768029
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic endocrine tumors-c-erb B2 (Her-2/neu), bcl-2, and p-53 immunohistochemical testing and their value in assessing prognosis.
Proca DM; Frankel WL
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):44-7. PubMed ID: 18091321
[TBL] [Abstract][Full Text] [Related]
3. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer.
Demirbaş S; Sücüllü I; Yildirim S; Celenk T
Turk J Gastroenterol; 2006 Mar; 17(1):13-9. PubMed ID: 16830272
[TBL] [Abstract][Full Text] [Related]
4. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M
Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2.
Sakr SA; Mahran HA; Fahmy AM; El-Kholy MA; Meawad M
Biomed Pharmacother; 2015 Dec; 76():73-81. PubMed ID: 26653553
[TBL] [Abstract][Full Text] [Related]
6. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas.
Botelho CH; Magalhães AV; Mello PA; Schmitt FC; Casulari LA
Arq Neuropsiquiatr; 2006 Mar; 64(1):60-6. PubMed ID: 16622555
[TBL] [Abstract][Full Text] [Related]
8. The oncoproteins c-erb-B2, c-fos and the tumour suppressor protein p53 in human embryos and fetuses.
Miosge N; Schneider W; Götz W; Herken R
Anat Embryol (Berl); 1997 Apr; 195(4):345-52. PubMed ID: 9108200
[TBL] [Abstract][Full Text] [Related]
9. [Expression of bcl-2, c-erbB2, and p53 protein in cervical epithelial carcinogenesis].
Tang ZH; Cai QF; Ye XA
Ai Zheng; 2003 Oct; 22(10):1057-61. PubMed ID: 14558950
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies.
Nagler RM; Kerner H; Ben-Eliezer S; Minkov I; Ben-Itzhak O
Oncology; 2003; 64(4):389-98. PubMed ID: 12759537
[TBL] [Abstract][Full Text] [Related]
11. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
12. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
13. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time.
Heinze T; Jonas S; Kärsten A; Neuhaus P
Anticancer Res; 1999; 19(4A):2501-3. PubMed ID: 10470182
[TBL] [Abstract][Full Text] [Related]
14. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
15. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
18. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas.
de Krijger RR; van der Harst E; van der Ham F; Stijnen T; Dinjens WN; Koper JW; Bruining HA; Lamberts SW; Bosman FT
J Pathol; 1999 May; 188(1):51-5. PubMed ID: 10398140
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
